GlassScriptPhysician profile
Tony Mammen
NPI 1194948356
$6,094.33
in general payments reported to CMS, 2019-2025
37 companies · $577 in 2025
The $577 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $822 · 2020: $615 · 2021: $628 · 2022: $745 · 2023: $818 · 2024: $1,889 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,247 · Travel and Lodging: $922 · Grant: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,247.34 |
| Travel and Lodging | $922.42 |
| Grant | $113.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $1,534.30 | 2024-2025 | Aquabeam System |
| Abbvie INC. | $473.31 | 2019-2025 | |
| Janssen Biotech, INC. | $407.39 | 2019-2024 | Erleada, Akeega |
| Astellas Pharma US INC | $398.74 | 2019-2021 | |
| Boston Scientific Corporation | $395.47 | 2019-2025 | Spaceoar Vue System - 10ml, Lithovue |
| Biotissue Holdings INC. | $372.58 | 2023 | |
| C. R. Bard, INC. & Subsidiaries | $219.76 | 2020-2021 | |
| Blue Earth Diagnostics | $217.28 | 2019-2022 | |
| Teleflex LLC | $204.91 | 2022-2025 | Urolift, Barrigel |
| Myovant Sciences INC. | $183.96 | 2021-2022 | |
| Olympus America INC. | $164.92 | 2024-2025 | Itind System |
| Axonics, INC. | $142.00 | 2022-2024 | Bulkamid |
| Sun Pharmaceutical Industries INC. | $137.00 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $128.79 | 2023-2024 | Orgovyx |
| Neotract INC. | $117.42 | 2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $100.48 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $98.48 | 2019 | |
| Coloplast Corp | $96.52 | 2022-2023 | Speedicath |
| Merck Sharp & Dohme LLC | $90.70 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $77.50 | 2019-2023 | |
| Endo Pharmaceuticals INC. | $74.74 | 2019-2021 | |
| Verity Pharmaceuticals INC. | $52.38 | 2023-2024 | Trelstar |
| Innovation Technologies INC | $48.20 | 2022 | |
| Antares Pharma, INC. | $45.64 | 2022-2023 | Nocdurna, Xyosted, Tlando |
| Healthtronics Stone Solutions, LLC | $41.21 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $35.42 | 2020-2021 | |
| Agiliti Surgical, INC. | $30.43 | 2019 | |
| Clarus Therapeutics INC. | $29.57 | 2021 | |
| Angiodynamics, INC. | $28.77 | 2023 | Nanoknife |
| Amgen INC. | $25.56 | 2019 | |
| Urogen Pharma, INC. | $24.04 | 2023 | Jelmyto |
| Urovant Sciences INC | $21.60 | 2022 | |
| Genzyme Corporation | $17.62 | 2019 | |
| Myriad Genetic Laboratories, INC. | $15.66 | 2022 | |
| 180 Medical, INC. | $15.61 | 2019 | |
| Janssen Scientific Affairs, LLC | $13.59 | 2020 | |
| Progenics Pharmaceuticals, INC. | $12.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tony Mammen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.